FIELD: medicine.
SUBSTANCE: group of inventions refers to oncology. Following is proposed: a method for classifying a malignant tumor disease comprising quantifying the expression of carbonic anhydrase IX (CAIX) in a tumor sample by staining the tumor cells and determining a CAIX score according to the formula, comparison of this CAIX score with a pre-defined CAIX score ≥ 2.0 and the classification/definition of a malignant tumor disease as being treated with a compound targeted to CAIX, if the CAIX score exceeds a predetermined threshold; and a method of treating the same, comprising the said method for classifying a malignant tumor diseaseas being treated with a compound targeted to CAIX (e.g., a girentuximab-antibody).
EFFECT: case of CAIX score ≥ 2_6, which combines the expression of the CAIX antigen with the intensity of staining, has a statistically significant therapeutic effect when treated with anti-CAIX girentuximab-antibody and in predicting and assessing the ratio of benefit and risk from treatment.
14 cl, 4 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED ADJUVANT THERAPY OF G250 EXPRESSING TUMOURS | 2005 |
|
RU2519340C2 |
| IMPROVED SUPPORTING THERAPY OF TUMOURS EXPRESSING G250 | 2005 |
|
RU2371198C2 |
| SELECTIVE DETECTION OF BONE METASTASES IN CLEAR CELL RENAL CELL ADENOCARCINOMA | 2010 |
|
RU2536290C2 |
| ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6 | 2012 |
|
RU2676731C2 |
| ANNEXIN A3 AUTOIMMUNE REGULATION OF PROSTATE CANCER | 2008 |
|
RU2484482C2 |
| DIAGNOSTICS AND TREATMENT OF MALIGNANT TUMOURS OF PANCREAS, OVARIES AND OTHER MALIGNANT TUMOURS | 2009 |
|
RU2556129C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| METHOD FOR CANCER DETECTION | 2013 |
|
RU2646466C2 |
| METHOD FOR CANCER DETECTION | 2013 |
|
RU2646464C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
